Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator

被引:2
|
作者
Yang, Shengwen [1 ,2 ]
Zhao, Junhan [3 ]
Liu, Xi [4 ]
Wang, Jing [3 ]
Gu, Min [3 ]
Cai, Chi [3 ]
Niu, Hongxia [3 ]
Chen, Liang [5 ]
Hua, Wei [3 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Heart Ctr, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Chaoyang Hosp, Beijing Key Lab Hypertens, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Arrhythmia Ctr, Arrhythmia Ctr,State Key Lab Cardiovasc Dis,Fuwai, Beijing, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, China Natl Clin Res Ctr Intervent Med,Dept Cardiol, Shanghai, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Dept Cardiac Surg,State Key Lab Cardiovasc Dis, Beijing, Peoples R China
基金
中国国家自然科学基金;
关键词
Implantable cardioverter defibrillator; Ventricular tachyarrhythmia; Metabolomics; Metabolites; SUDDEN CARDIAC DEATH; RISK STRATIFICATION; N-ACETYLASPARTATE; PHOSPHATIDIC-ACID; EJECTION FRACTION; DISEASE; OVEREXPRESSION; ABNORMALITIES; METABOLISM; COMMITTEE;
D O I
10.1007/s12265-023-10413-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Implantable cardioverter defibrillators (ICDs) reduce sudden cardiac death (SCD) when patients experience life-threatening ventricular arrhythmias ( LTVA). However, current strategies determining ICD patient selection and risk stratification are inefficient. We used metabolomics to assess whether dysregulated metabolites are associated with LTVA and identify potential biomarkers. Baseline plasma samples were collected from 72 patients receiving ICDs. Over a median follow-up of 524.0 days (range 239.0-705.5), LTVA occurred in 23 ( 31.9%) patients (22 effective ICD treatments and 1 SCD). After confounding risk factors adjustment for age, smoking, secondary prevention, and creatine kinase MB, 23 metabolites were significantly associated with LTVA. Pathway analysis revealed LTVA associations with disrupted metabolism of glycine, serine, threonine, and branched chain amino acids. Pathway enrichment analysis identified a panel of 6 metabolites that potentially predicted LTVA, with an area under the receiver operating characteristic curve of 0.8. Future studies are necessary on biological mechanisms and potential clinical use.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 50 条
  • [1] Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator
    Shengwen Yang
    Junhan Zhao
    Xi Liu
    Jing Wang
    Min Gu
    Chi Cai
    Hongxia Niu
    Liang Chen
    Wei Hua
    Journal of Cardiovascular Translational Research, 2024, 17 : 91 - 101
  • [2] Systolic Blood Pressure and Risk for Ventricular Arrhythmia in Patients With an Implantable Cardioverter Defibrillator
    Beinart, Roy
    Goldenberg, Ilan
    Younis, Arwa
    McNitt, Scott
    Huang, David
    Aktas, Mehmet K.
    Spencer, Rosero
    Kutyifa, Valentina
    Nof, Eyal
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 143 : 74 - 79
  • [3] Prevalence of anxiety and risk associated with ventricular arrhythmia in patients with an implantable cardioverter defibrillator
    Habibovic, M.
    Pedersen, S. S.
    Broers, E. R.
    Alings, M.
    Theuns, D. A. M. J.
    van Der Voort, P. H.
    Bouwels, L.
    Herrman, J-P
    Denollet, J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 310 : 80 - 85
  • [4] Ventricular arrhythmia storm in the era of implantable cardioverter-defibrillator
    Looi, Khang-Li
    Tang, Anthony
    Agarwal, Sharad
    POSTGRADUATE MEDICAL JOURNAL, 2015, 91 (1079) : 519 - 526
  • [5] Celivarone in patients with an implantable cardioverter-defibrillator: Adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions
    Gojkovic, Olivera
    Aliot, Etienne M.
    Capucci, Alessandro
    Connolly, Stuart J.
    Crijns, Harry
    Hohnloser, Stefan H.
    Kulakowski, Piotr
    Roy, Denis
    Radzik, David
    Singh, Bramah N.
    Kowey, Peter R.
    HEART RHYTHM, 2012, 9 (02) : 217 - U2
  • [6] Impact of Myocardial Bridge on Life-Threatening Ventricular Arrhythmia in Patients With Implantable Cardioverter Defibrillator
    Okada, Kozo
    Hibi, Kiyoshi
    Ogino, Yutaka
    Maejima, Nobuhiko
    Kikuchi, Shinnosuke
    Kirigaya, Hidekuni
    Kirigaya, Jin
    Sato, Ryosuke
    Nakahashi, Hidefumi
    Minamimoto, Yugo
    Kimura, Yuichiro
    Akiyama, Eiichi
    Matsuzawa, Yasushi
    Iwahashi, Noriaki
    Kosuge, Masami
    Ebina, Toshiaki
    Tamura, Kouichi
    Kimura, Kazuo
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (21):
  • [7] Clinical Implications of an Implantable Cardioverter-Defibrillator in Patients With Vasospastic Angina and Lethal Ventricular Arrhythmia
    Matsue, Yuya
    Suzuki, Makoto
    Nishizaki, Mitsuhiro
    Hojo, Rintaro
    Hashimoto, Yuji
    Sakurada, Harumizu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (10) : 908 - 913
  • [8] Ventricular arrhythmia: Role of the implantable cardioverter defibrillator and radiofrequency ablation in addition to drugs
    Fischer, A
    Verma, R
    Gomes, JA
    Mehta, D
    MOUNT SINAI JOURNAL OF MEDICINE, 2002, 69 (04): : 197 - 207
  • [9] Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator
    Noordman, Alwin B. P.
    Maass, Alexander H.
    Groenveld, Hessel
    Mulder, Bart A.
    Rienstra, Michiel
    Blaauw, Yuri
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [10] ARRHYTHMIA RECURRENCE IN NONINDUCIBLE PATIENTS RECEIVING THE AUTOMATIC IMPLANTABLE CARDIOVERTER DEFIBRILLATOR
    KADRI, N
    GILBERT, C
    CACERES, J
    NIAZI, I
    WERNER, P
    AKHTAR, M
    CIRCULATION, 1987, 76 (04) : 309 - 309